Omeros (OMER)

• Market cap: $724M
• 1 day: -2.63%
• 5 days: -3.1%
• 1 month: 7.29%
• 3 months: -12.04%
• 6 months: -20.68%
• Year to date: -38.89%
• 1 year: 154.71%
• 5 years: -29.85%
• 10 years: -10.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Employees: 175